直接口服抗凝剂在慢性心力衰竭和心房中具有性作用:机器学习分析
Marco Mele1,2, Antonietta Mele1, Paola Imbrici1
1Department of Pharmacy-Drug Sciences, University of Bari, Via Orabona 4, 70125 Bari, Italy.
Molecules (Basel, Switzerland)
|June 19, 2024
概括
在心脏衰竭 (HF) 的心房动 (AF) 患者中,从华法林转换为直接作用的口服抗凝剂 (DOAC) 显示了除了抗凝药之外的积极影响. 机器学习分析揭示了心脏重塑和炎症标志物的好处.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 数据科学数据科学数据科学
背景情况:
- 口服抗凝药疗法 (OAT) 使用维生素K抗剂 (VKA) 和直接作用的口服抗凝剂 (DOAC) 治疗心房动 (AF).
- 由于大出血的风险较低,与VKA相比,越来越多地使用DOAC.
- 切换OAT在AF患者中很常见,但了解它对那些同时存在心力衰竭 (HF) 的人的影响至关重要.
研究的目的:
- 评估从华法林转换为DOACs在患有HF的AF患者的影响.
- 评估对心脏重塑,临床状态,内皮功能和炎症生物标志物的影响.
- 为了识别除了抗凝固之外的DOACs的益处.
主要方法:
- 临床数据库的机器学习 (ML) 分析.
- 对涉及OAT切换的患者数据的回顾性分析.
- 评估心脏,临床,内皮和炎症参数.
主要成果:
- 从华法林切换到DOACs的治疗转换在患有HF的AF患者中显示出积极的影响.
- ML分析发现对心脏重塑和炎症生物标志物的有益影响.
- DOACs表现出除了它们的抗凝活性之外的类效应.
结论:
- 在患有HF的AF患者中切换到DOAC提供了除了抗凝药之外的好处.
- DOACs积极影响心脏重塑和炎症概况.
- 在这种患者群体中,需要进一步了解DOACs的类作用.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
675
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
675
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
420
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
420
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
517
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
517
Cardiovascular Drugs: Classification based on Therapeutic Indications
2.3K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.3K


